Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors Sep 28, 2023 8:00am EDT
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference Sep 07, 2023 8:00am EDT
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock Aug 23, 2023 8:00am EDT
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Aug 17, 2023 8:00am EDT
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update Aug 16, 2023 8:00am EDT
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000 Jun 07, 2023 9:21am EDT
Baudax Bio Reports First Quarter Financial Results and Provides Business Update May 12, 2023 8:32am EDT
